Leukotuximab

Drug Profile

Leukotuximab

Alternative Names: Anti-JL1 monoclonal antibody; ART-140; DNP-001; EGX-040; EGX-140; SSS-19

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Seoul
  • Developer 3SBio; Arana Therapeutics; DiNonA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action JL1 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Leukaemia

Most Recent Events

  • 12 May 2016 Preclinical trials in Leukaemia in China (Parenteral)
  • 13 Aug 2014 No development reported - Preclinical for Leukaemia in Australia (Parenteral)
  • 07 Aug 2014 Leukotuximab licensed to 3SBio in China (including Taiwan, Hong Kong and Macau) and Middle East (excluding Cyprus, Egypt, Israel and Turkey)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top